Skip to main content

Genital Nullification — AMAB (Penectomy + Bilateral Orchiectomy + Scrotectomy + Perineal Urethrostomy)

Genital nullification (also termed nullo surgery or gender nullification) for AMAB individuals is the removal of penis, testes, and scrotum without creation of a neovagina, resulting in a smooth perineal contour with a perineal urethrostomy (PU) for urinary function.[1] It is an individually customised gender-affirming procedure falling outside the binary surgical options (vaginoplasty or stand-alone orchiectomy) and is most commonly sought by nonbinary or gender-diverse individuals.

This is the dedicated atlas page. For the broader variant-GGAS framework and decision matrix, see Non-Binary / Nullification Gender-Affirming Surgery. For the perineal-urethrostomy component, see 7-Flap Perineal Urethrostomy and Blandy Perineal Urethrostomy. For the orchiectomy component, see Bilateral Simple Orchiectomy. For the canal-creating alternative (external feminine appearance without vagina), see Zero-Depth Vulvoplasty.

Indication and Surgical Goal​

The goal is absence of external genital structures with a smooth, aesthetically neutral perineum and seated-position voiding via a perineal urethrostomy.[1]

This is distinct from:

  • Zero-depth / shallow-depth vulvoplasty — which creates external vulvar structures (labia, clitoral hood, neoclitoris) but no vaginal canal.[1]
  • Full-depth vaginoplasty — neovaginal canal + vulvar structures.
  • Stand-alone bilateral orchiectomy — testes removed but penis and scrotum retained.

Nullification specifically aims for the absence of any genital structures.

Eligibility​

WPATH SOC v8 (2022) recognises that gender-affirming surgical goals are highly individual and that nonbinary individuals may seek procedures that do not conform to traditional binary options.[2][3] General eligibility criteria for irreversible genital surgery include:[4]

  • Persistent, well-documented gender dysphoria.
  • Capacity for informed consent.
  • Well-managed coexisting medical and mental-health conditions.
  • Typically two independent mental-health-professional letters of recommendation.
  • ≥ 12 mo hormone therapy generally recommended for gonadectomy, though individualised.[4][3]

Pezzoli 2026 Delphi consensus on feminising genital surgery in AMAB individuals (largely applicable to nullification) identified BMI > 24.9 kg/m², diabetes, smoking, and cardiovascular disease as significant risk factors for postoperative complications; advanced age alone was not considered a contraindication.[5]

Surgical Technique — Step by Step​

Per Ascha 2024 individually customised genital procedures (the central GAS-specific reference for this operation):[1]

1. Bilateral orchiectomy​

Standard inguinal or scrotal approach; spermatic cords ligated and divided. Cross-link to Bilateral Simple Orchiectomy for full technique. Saltman 2023 NSQIP (n = 246 transgender orchiectomies): 3.7% overall complication rate, comparable to cisgender orchiectomy; safely performed as outpatient.[6]

2. Penectomy​

  • Corpora cavernosa dissected from their attachments and excised.
  • Dorsal neurovascular bundle ligated (unlike feminising-vaginoplasty disassembly, no clitoroplasty target — the NVB is sacrificed rather than preserved on a glans flap).
  • Urethra carefully dissected free from the corpus spongiosum distally.

3. Scrotectomy​

Redundant scrotal skin excised. Depending on surgeon preference, some scrotal / perineal skin may be preserved for wound closure and contouring.

4. Perineal urethrostomy creation​

The bulbar urethra is mobilised and brought to the perineum; meatus spatulated and matured to the perineal skin to create a widely patent stoma. Preservation of the dorsal urethral plate and longitudinal blood supply is critical to minimising stenosis risk:[7][8]

  • Myers 2011 dorsal-plate-preservation technique — 83% primary success; 93% secondary success.[8]
  • Joshi / Morey 2024 algorithmic midline approach — 95.1% success with only 4.9% requiring re-intervention.[7]

Technique selection follows the same algorithmic framework as cisgender PU — see the canonical 7-Flap Perineal Urethrostomy (modern algorithmic midline approach; French / Hudak / Morey 2011) and Blandy Perineal Urethrostomy (classical inverted-U flap; Blandy 1968) pages for technique detail.

5. Closure​

Remaining skin edges approximated to create a smooth, flat perineal contour. The goal is an aesthetically neutral genital area.

Perioperative Management​

Per the Pezzoli 2026 Delphi consensus on feminising genital surgery in AMAB individuals (largely applicable to nullification):[5]

  • Preoperative — genital hair removal recommended; structured counselling on wound care, voiding changes, and irreversibility essential.
  • Thromboprophylaxis — enoxaparin prophylaxis recommended.[5]
  • Catheterisation — urethral catheter typically maintained for 3–5 days per Delphi (feminising GAS); PU-specific literature reports 10–21 days (median 15) in the penile-cancer cohort.[5][9]
  • Hospital stay — varies; stand-alone orchiectomy is outpatient; combined nullification may require short inpatient stay (median 8 d in Falcone penectomy + PU series — oncologic cohort).[6][9]
  • Pelvic-floor PT — pre- and post-operative pelvic-floor PT recommended.[5]
  • No dilation required — unlike vaginoplasty, no neovaginal canal means no lifelong dilation maintenance burden (a significant advantage).

Complications​

Component-procedure complication data:

Orchiectomy (Saltman NSQIP n = 246 transgender)[6]​

  • Overall 3.7% complication rate; no significant difference from cisgender orchiectomy for non-oncologic indications.
  • Hematoma, wound infection, rare DVT.

Perineal urethrostomy (aggregated)[10][11][7][8]​

ComplicationIncidenceManagement
Stomal stenosis5–18%Dilation or surgical revision
Wound infection~11%Antibiotics, wound care
Wound dehiscence~4%Conservative or surgical
Urinary spraying / misdirectionVariablePositional adjustment, revision
Urinary incontinenceRare (median ICIQ 0)Pelvic-floor PT

Largest multicentre series (de Vries 2021 penile-cancer n = 299): stenosis in 12%; 74% of stenoses required surgical revision; median time to revision 6.1 mo; stenoses rare after 2 yr follow-up.[10] Prior radiation therapy is the strongest stenosis risk factor (OR 11.2)[8] — likely confers lower stenosis risk in the gender-affirming population, which is typically younger and without radiation history.

Urinary Function After PU​

Long-term urological outcomes are well-characterised:[11][12][7][13]

  • Voiding position — all patients void seated. Morey series: 76% unbothered by the change; 82% reported improvement in overall health.[7]
  • Voiding function — significant LUTS improvement. Shinchi 2021: Qmax 3.8 → 17.6 mL/s; PVR 77.6 → 21.3 mL.[13]
  • Continence — generally well preserved. Klemm 2024 median ICIQ-UI 0 (range 0–21) at median 55-mo follow-up.[11]
  • Retreatment-free survival — 84–95% depending on technique and population.[11][7]
  • Patient satisfaction — consistently 84–86% satisfied or very satisfied.[11][7][13]

Psychological and Quality-of-Life Outcomes​

Nullification-specific PRO data are limited, but the broader GAS literature provides strong support:

  • Almazan / Keuroghlian US Transgender Survey n = 27,715 — GAS associated with lower psychological distress (aOR 0.58), lower past-year suicidal ideation (aOR 0.56), lower smoking (aOR 0.65).[14]
  • Cooney 2025 SR (13 studies) — all 4 QoL studies showed statistically significant improvement; all 5 gender-dysphoria studies showed improved gender congruence after surgery.[15]
  • Hung 2023 validated GAS-specific instrument — 2.8% regret rate across GAS.[16]
  • Pletta 2025 (large cohort) — reproductive surgeries (including gonadectomy) rated most satisfactory across all gender-identity groups (mean 4.6/5).[17]

Lifelong Postoperative Care​

After nullification:[18]

  • Hormone replacement therapy is mandatory after bilateral orchiectomy. Options include estrogen (feminising) or testosterone. Without sex-hormone replacement, patients are at risk for osteoporosis, cardiovascular disease, metabolic syndrome, and cognitive changes. DEXA bone-density monitoring per standard guidelines.
  • Prostate screening — prostate is retained; screening follows standard age and risk guidelines. Digital rectal examination is the standard approach (unlike post-vaginoplasty patients where vaginal palpation is used).[18]
  • PU surveillance — regular follow-up first 1–2 years for stenosis (most stenoses present within 18 mo). Annual or as-needed follow-up thereafter.[10]
  • UTI surveillance — shortened urethra may increase UTI susceptibility; standard treatment guidelines apply.[18]
  • Psychosocial support — particularly during adjustment period; patients with pre-existing mental-health diagnoses may have worse PROs and warrant closer monitoring.[19]

Access and Ethical Considerations​

Only a small number of surgeons currently offer genital nullification — falls outside the standard binary surgical menu. Ascha 2024 reported on just 16 patients undergoing individually customised procedures across their institution.[1]

Nonbinary AMAB individuals have the lowest rate of prior GAS of any gender-identity group — only 17.8% had received any form of GAS in Pletta 2025, vs 58.3% of transgender men.[17] Disparity likely reflects both limited surgical availability and insurance barriers for nonbinary-specific procedures (many policies are structured around binary surgical pathways).[20][1]

Evidence Limitations​

  • Ascha 2024 (n = 16) is the central GAS-specific reference but the cohort spans all customised procedures, not nullification specifically — formal subgroup outcomes data not reported.[1]
  • PU outcomes data are largely extrapolated from cisgender reconstructive-urology and penile-cancer cohorts (Joshi-Morey, Myers, de Vries, Klemm, Shinchi) — younger transmasculine / nonbinary patients without radiation history may have lower stenosis risk.[7][8][10][11][13]
  • No nullification-specific PROMs validated in the nonbinary population.
  • Pezzoli 2026 Delphi consensus addresses feminising genital surgery, not nullification specifically — perioperative recommendations largely transferable but not formally validated for this indication.[5]

References​

1. Ascha M, Rigsby S, Shoham M, et al. Individually customized gender-affirming genital procedures: techniques and considerations. J Sex Med. 2024;21(9):827–834. doi:10.1093/jsxmed/qdae075

2. Jha S, Bouman WP. Introduction to healthcare for transgender and gender-diverse people. Best Pract Res Clin Obstet Gynaecol. 2023;87:102299. doi:10.1016/j.bpobgyn.2022.102299

3. Dakkak M, Kriegel II DL, Tauches K. Caring for transgender and gender-diverse people: guidelines from WPATH. Am Fam Physician. 2023;108(6):626–629.

4. Wylie K, Knudson G, Khan SI, et al. Serving transgender people: clinical care considerations and service delivery models in transgender health. Lancet. 2016;388(10042):401–411. doi:10.1016/S0140-6736(16)00682-6

5. Pezzoli M, Lo Re M, Pizziconi V, et al. International Delphi consensus on feminising genital surgery in assigned-male-at-birth individuals. BJU Int. 2026. doi:10.1111/bju.70196

6. Saltman AJ, Dorante MI, Jonczyk MM, et al. Outcomes of orchiectomy for gender-affirming surgery: a National Surgical Quality Improvement Program study. Urology. 2023;180:98–104. doi:10.1016/j.urology.2023.07.003

7. Joshi EG, VanDyke ME, Langford BT, Franzen BP, Morey AF. Algorithmic midline approach to perineal urethrostomy is associated with long-term success and high patient satisfaction. Urology. 2024;190:133–139. doi:10.1016/j.urology.2024.03.016

8. Myers JB, Porten SP, McAninch JW. The outcomes of perineal urethrostomy with preservation of the dorsal urethral plate and urethral blood supply. Urology. 2011;77(5):1223–1227. doi:10.1016/j.urology.2010.10.041

9. Falcone M, Preto M, Ferro I, et al. Surgical and functional outcomes of penile amputation and perineal urethrostomy configuration in invasive penile cancer. Urology. 2023;177:227. doi:10.1016/j.urology.2023.04.005

10. de Vries HM, Chipollini J, Slongo J, et al. Outcomes of perineal urethrostomy for penile cancer: a 20-year international multicenter experience. Urol Oncol. 2021;39(8):500.e9–500.e13. doi:10.1016/j.urolonc.2021.04.023

11. Klemm J, Dahlem R, Schulz RJ, et al. Perineal urethrostomy for complex urethral strictures: long-term patient-reported outcomes from a reconstructive referral centre and a scoping literature review. J Urol. 2024;212(5):738–748. doi:10.1097/JU.0000000000004169

12. Murphy GP, Fergus KB, Gaither TW, et al. Urinary and sexual function after perineal urethrostomy for urethral stricture disease: an analysis from the TURNS. J Urol. 2019;201(5):956–961. doi:10.1097/JU.0000000000000027

13. Shinchi M, Horiguchi A, Ojima K, et al. Evaluation of the efficacy of perineal urethrostomy for patients with anterior urethral stricture: insights from surgical and patient-reported outcomes. World J Urol. 2021;39(12):4443–4448. doi:10.1007/s00345-021-03795-2

14. Almazan AN, Keuroghlian AS. Association between gender-affirming surgeries and mental health outcomes. JAMA Surg. 2021;156(7):611–618. doi:10.1001/jamasurg.2021.0952

15. Cooney EE, Muschialli L, Yeh PT, et al. Provision of gender-affirming care for trans and gender-diverse adults: a systematic review of health and quality-of-life outcomes, values and preferences, and costs. EClinicalMedicine. 2025;88:103458. doi:10.1016/j.eclinm.2025.103458

16. Hung YC, Park BC, Assi PE, et al. Multidimensional assessment of patient-reported outcomes after gender-affirming surgeries using a validated instrument. Ann Plast Surg. 2023;91(5):604–608. doi:10.1097/SAP.0000000000003652

17. Pletta DR, Quint M, Radix AE, et al. Gender-affirming surgical history, satisfaction, and unmet needs among transgender adults. JAMA Netw Open. 2025;8(9):e2532494. doi:10.1001/jamanetworkopen.2025.32494

18. Jackson Q, Yedlinsky NT, Gray M. Lifelong care of patients after gender-affirming surgery. Am Fam Physician. 2024;109(6):560–565.

19. Haley C, Roblee CV, Blasdel G, et al. Gender-affirming vaginoplasty improves quality of life in transfeminine individuals: a single-centre prospective study. Ann Surg. 2025. doi:10.1097/SLA.0000000000006988

20. Committee on Gynecologic Practice and Committee on Health Care for Underserved Women. Health care for transgender and gender diverse individuals: ACOG Committee Opinion, Number 823. Obstet Gynecol. 2021;137(3):e75–e88. doi:10.1097/AOG.0000000000004294